Vertex Pharmaceuticals Incorporated (0QZU.L) LSE
425.00
-3.84(-0.90%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vertex Pharmaceuticals Incorporated
Address
50 Northern Avenue
Boston, MA 02210
United States of America (the)
Phone
617 341 6100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6100
First IPO Date
November 10, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Reshma Kewalramani FASN | Chief Executive Officer, President & Director | 6.14M | 1973 |
| Jeffrey Marc Leiden | Executive Chairman | 70,000 | 1956 |
| Amit K. Sachdev | Executive Vice President & Chief Patient and External Affairs Officer | 1.88M | 1968 |
| Ourania Tatsis | Executive Vice President and Chief Regulatory & Quality Officer | 2.07M | 1970 |
| Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | 2.27M | 1963 |
| David Altshuler | Executive Officer | 2.39M | 1965 |
| Mark Bunnage D.Phil | Executive Vice President & Chief Scientific Officer | 2.39M | 1969 |
| Charles F. Wagner Jr. | Executive Vice President, Chief Operating Officer & Chief Financial Officer | 2.99M | 1968 |
| Edward Morrow Atkinson | EVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | 0 | 1966 |
| Duncan J. McKechnie | Chief Commercial Officer, Head of North America Commercial & Executive VP | 0 | 1969 |
| Felicia Pagliuca | Senior Vice President of Cell & Genetic Therapy Research | 0 | N/A |
| Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | 0 | 1978 |
| Kristen C. Ambrose | Senior Vice President & Chief Accounting Officer | 0 | 1977 |
| Miroslava Atanassova Minkova | Executive Director of Investor Relations | 0 | N/A |
| Nina Devlin | Senior Vice President & Chief Communications Officer | 0 | N/A |
| Susie Lisa | Senior Vice President of Investor Relations | 0 | N/A |
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
